Comparison of six risk scores for the prediction of atrial fibrillation recurrence after cryoballoon-based ablation and development of a simplified method, the 0-1-2 PL score

比较六种风险评分在预测冷冻球囊消融术后房颤复发方面的效果,并开发一种简化的方法——0-1-2 PL评分。

阅读:2

Abstract

INTRODUCTION: There are several prognostic scores for the assessment of risk of atrial fibrillation (AF) recurrence post ablation procedure. However, the use of these complex scores is difficult and the validation on different populations brought divergent results. Our goal was to compare the performance of these risk scores as the basis for the development of a new, simplified score based only on few universally predictive variables. METHODS: All cryoballoon-based AF ablations performed in a single-center over a 10-year period were prospectively analyzed with regard to AF recurrence. This served to analyze the performance of APPLE, CAAP-AF, SCALE-CryoAF, MB-LATER, CHADS(2), and CHA(2)DS(2)-VASc risk scores. RESULTS: A total of 597 patients, mostly (78.1%) with paroxysmal AF were studied. Analyzed risk scores performed poorer than in the original publications because some risk factors were not predictive of AF recurrence. A simplified score named 0-1-2 PL, composed of just two universally predictive variables, AF type (1 point for Persistent AF) and LA dimension (1 point for LA size >45 mm) was developed. The 0-1-2 PL score stratified patients into low risk (0 points), intermediate risk (1 point), and high risk categories (2 points) which were related to a 2-year risk of AF recurrence of 21%, 37%, and 55%, respectively. This score had C-statistics (0.620) higher/comparable to other investigated much more complex scores. CONCLUSION: The assessment of risk of AF recurrence at the pre-ablation stage can be simplified without compromising accuracy. This could help to popularize risk assessment and standardization of AF management.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。